Compliance of imipenem and meropenem administration with the national antimicrobial stewardship program in a referral teaching hospital in Iran

References

• Zhen X, Lundborg CS, Sun X, et al. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. Antimicrob Resist Infect Control. 2019;8(1):1–23.
   PubMed Web of Science ®Google Scholar
• O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016.
   Google Scholar
• Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PloS One. 2017;12(12):e0189621.
   PubMed Web of Science ®Google Scholar
• Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903.
   PubMed Web of Science ®Google Scholar
• Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.
   PubMed Web of Science ®Google Scholar
• Hofer U. The cost of antimicrobial resistance. Nature Rev Microbiol. 2019;17(1):3.
   PubMedGoogle Scholar
• Towse A, Hoyle CK, Goodall J, et al. Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. Health Policy. 2017;121(10):1025–1030.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: implications for the future. Clinl Infect Dis. 2004;38(9):1279–1286.
   PubMed Web of Science ®Google Scholar
• Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6(5):427–430.
   PubMed Web of Science ®Google Scholar
• O’Neill J. Securing new drugs for future generations: the pipeline of antibiotics. 2015. 2017.
   Google Scholar
• Kirchhelle C, Atkinson P, Broom A, et al. Setting the standard: multidisciplinary hallmarks for structural, equitable and tracked antibiotic policy. BMJ Glob Health. 2020;5(9):e003091.
   PubMed Web of Science ®Google Scholar
• Rogers Van Katwyk S, Grimshaw JM, Nkangu M, et al. Government policy interventions to reduce human antimicrobial use: a systematic review and evidence map. PLoS Med. 2019;16(6):e1002819.
   PubMed Web of Science ®Google Scholar
• Godman B, Egwuenu A, Haque M, et al. Strategies to improve antimicrobial utilization with a special focus on developing countries. Life. 2021;11(6):528.
   PubMedGoogle Scholar
• Hsia Y, Sharland M, Jackson C, et al. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019;19(1):67–75.
   PubMed Web of Science ®Google Scholar
• Sharland M, Gandra S, Huttner B, et al. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infect Dis. 2019;19(12):1278–1280.
   PubMed Web of Science ®Google Scholar
• Sharland M, Pulcini C, Harbarth S, et al. 21st WHO expert committee on selection and use of essential medicines. Classifying antibiotics in the WHO essential medicines list for optimal use-be AWaRe. Lancet Infect Dis. 2018;18(1):18–20.
   PubMed Web of Science ®Google Scholar
• Manderson L. Prescribing, care and resistance: antibiotic use in urban South Africa. Humanities and Social Sciences Communications. 2020;7(1):1–10
   Google Scholar
• Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clinl Infect Dis. 2007;44(2):159–177.
   PubMed Web of Science ®Google Scholar
• Malani AN, Richards PG, Kapila S, et al. Clinical and economic outcomes from a community hospital’s antimicrobial stewardship program. Am J Infect Control. 2013;41(2):145–148.
   PubMed Web of Science ®Google Scholar
• Cox JA, Vlieghe E, Mendelson M, et al. Antibiotic stewardship in low-and middle-income countries: the same but different? Clin Microbiol Infect. 2017;23(11):812–818.
   PubMed Web of Science ®Google Scholar
• Fadare JO, Ogunleye O, Iliyasu G, et al. Status of antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: findings and implications. J Glob Antimicrob Resist. 2019;17:132–136.
   PubMed Web of Science ®Google Scholar
• Kalungia AC, Mwambula H, Munkombwe D, et al. Antimicrobial stewardship knowledge and perception among physicians and pharmacists at leading tertiary teaching hospitals in Zambia: implications for future policy and practice. J Chemother. 2019;31(7–8):378–387.
   PubMed Web of Science ®Google Scholar
• Holloway KA, Rosella L, Henry D. The impact of WHO essential medicines policies on inappropriate use of antibiotics. PLoS One. 2016;11(3):e0152020.
   PubMed Web of Science ®Google Scholar
• Ratanawijitrasin S, Soumerai SB, Weerasuriya K. Do national medicinal drug policies and essential drug programs improve drug use?: a review of experiences in developing countries. Soc Sci Med. 2001;53(7):831–844.
   PubMed Web of Science ®Google Scholar
• Versporten A, Zarb P, Caniaux I, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018;6(6):e619–e629.
   PubMed Web of Science ®Google Scholar
• Nakwatumbah S, Kibuule D, Godman B, et al. Compliance to guidelines for the prescribing of antibiotics in acute infections at Namibia’s national referral hospital: a pilot study and the implications. Expert Rev Anti Infect Ther. 2017;15(7):713–721.
   PubMed Web of Science ®Google Scholar
• Niaz Q, Godman B, Campbell S, et al. Compliance to prescribing guidelines among public health care facilities in Namibia; findings and implications. Int J Clin Pharm. 2020;42(4):1227–1236.
   PubMed Web of Science ®Google Scholar
• Organization WH. World report on ageing and health: World Health Organization; 2015. 2016.
   Google Scholar
• Abbasian H, Hajimolaali M, Yektadoost A, et al. Antibiotic utilization in Iran 2000–2016: pattern analysis and benchmarking with organization for economic co-operation and development countries. J Res Pharm Pract. 2019;8(3):162.
   PubMed Web of Science ®Google Scholar
• Mehtarpour M, Takian A, Eshrati B, et al. Control of antimicrobial resistance in Iran: the role of international factors. BMC Public Health. 2020;20(1):1–10.
   PubMed Web of Science ®Google Scholar
• Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21.
   PubMed Web of Science ®Google Scholar
• Li Y, Li J, Hu T, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China. Antimicrob Resist Infect Control. 2020;9(1):1–14.
   PubMed Web of Science ®Google Scholar
• Peyclit L, Baron SA, Rolain J-M. Drug repurposing to fight colistin and carbapenem-resistant bacteria. Front Cell Infect Microbiol. 2019;9:193.
   PubMed Web of Science ®Google Scholar
• Yang P, Chen Y, Jiang S, et al. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrob Resist Infect Control. 2018;7(1):1–7.
   PubMedGoogle Scholar
• Roca I, Akova M, Baquero F, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22–29.
   PubMedGoogle Scholar
• Moradi G, Gouya MM, Eshrati B, et al. National action plan of the Islamic Republic Of Iran for combating antimicrobial resistance during 2016–2021. Med J Islam Repub Iran. 2018;32(1):82.
   PubMedGoogle Scholar
• Sadatsharifi A, Davarpanah M-A, Namazi S, et al. Economic burden of inappropriate empiric antibiotic therapy: a report from Southern Iran. Risk Manag Healthc Policy. 2019;12:339.
   PubMed Web of Science ®Google Scholar
• Bizo PT, Dumitras D, Popa A. Evaluation of restricted antibiotic use in a hospital in Romania. Int J Clin Pharm. 2015;37(3):452–456.
   PubMed Web of Science ®Google Scholar
• Mahmoudi L, Sepasian A, Firouzabadi D, et al. The Impact of an Antibiotic Stewardship Program on the Consumption of Specific Antimicrobials and Their Cost Burden: a Hospital-wide Intervention. Risk Manag Healthc Policy. 2020;13:1701.
   PubMed Web of Science ®Google Scholar
• Salehifar E, Shiva A, Moshayedi M, et al. Drug use evaluation of Meropenem at a tertiary care university hospital: a report from Northern Iran. J Res Pharm Pract. 2015;4(4):222.
   PubMed Web of Science ®Google Scholar
• Amer MR, Akhras NS, Mahmood WA, et al. Antimicrobial stewardship program implementation in a medical intensive care unit at a tertiary care hospital in Saudi Arabia. Ann Saudi Med. 2013;33(6):547–554.
   PubMed Web of Science ®Google Scholar